Flu Vaccine A: The state will pay 48 million
The letters are left on Monday evening. Reportedly, the Health Minister Roselyne Bachelot has finalized negotiations there nearly three months with pharmaceutical companies. To date, the Government had decided to terminate 50 of the 94 million doses of vaccine against influenza A previously ordered.
Doses reserved – totaling approximately 700 million euros – in June and July 2009, at a time when the World Health recommended to the States two injections per person. A requirement under attack in November 2009. The European Agency for the Evaluation of Medicinal Products (EMEA) was then estimated that injection was sufficient. This change of foot forced the French government to reconsider its brutally volume orders. Last January, Roselyne Bachelot announced on TF1, the government would not pay the "50 million doses not delivered."A cold shower for the three laboratories involved: GSK, Sanofi Pasteur, Novartis.
Heard today in the Senate by the parliamentary commission of inquiry charged with shedding light on government management of the epidemic of influenza A, the Minister of Health outlining the results of negotiations.
The State should pay the final 48 million euro to pharmaceutical companies instead of 358 million euros initially planned for 50 million doses canceled. Conducted by the Institution of preparation and response to health emergencies (Eprus), negotiations were conducted by laboratory laboratory. "It was man enough, but correct," says one observer of the case. Logic in a big business. Especially that similar talks were held in many countries.In Europe, France and Great Britain are the last to not have fully resolved the issue.
Allowances equal to 16% of the amount set aside
The government immediately set the overall ceiling of compensation it was willing to pay 50 million euros payday loan no faxing . Given the low number of relevant doses (50 000), Baxter has escaped cancellation of orders. But with the three other laboratories, the negotiations were tough. Driven to the wall they demanded equal treatment. So that, finally, the Eprus set the maximum amount of compensation to 16% of the canceled order for each of the labs.
The Eprus and Swiss drugmaker Novartis have been finally agreed Monday. Novartis will receive 10.5 million euros, or about 16% of 65 million at stakeBoth parties waive any recourse to justice.
With GlaxoSmithKline (GSK), failing agreement, the government decided to unilaterally fix the compensation to 36 million euros. But the pill is hard to swallow for the British lab, which has collected 224 million euros if the services Roselyne Bachelot had not canceled the order of 32 million doses. GSK should take note of the proposal, but consider formally accept it.
Finally, negotiations have been particularly harsh with Sanofi-Pasteur. The world leader in vaccines against influenza had himself proposed to cancel the order of 9 million doses of an original total of 28 million.But the subsidiary of Sanofi-Aventis has found less pleasant to have to cancel another 2 million doses.
Unless last-minute deal, the government should send a notification on grounds similar to those of Novartis and GSK, is a payment of 2 million euros over the initial 12.5. Monday evening, the French lab was still hesitating to sign the proposed transaction or initiate an action.
ALSO READ:
"Influenza A: 22 big cities have the invoice to the State
"Influenza A: laboratories ready to deliver vaccines under
"Vaccine H1N1: Bachelot defends his change of strategy
"SPECIAL – All about the influenza A
Comments Off